# R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

> **NCT04842487** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 80 (estimated)

## Conditions studied

- DLBCL

## Interventions

- **DRUG:** R2-CHOP(Lenalidomide,Rituximab,cyclophosphamide，hydroxyldaunorubicin，Vincristine，Prednisone）)

## Key facts

- **NCT ID:** NCT04842487
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-10
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2021-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842487

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842487, "R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04842487. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*